Immunovant IMVT
NASDAQ IMVT
$33.65 -0.13 (-0.38%)
As of: Oct 1, 2026 · 3:59 PM EDT

Immunovant (IMVT) Non-Current Deffered Revenue (2019)

Updated

Immunovant (IMVT) reported Non-Current Deffered Revenue of $4.03 million for fiscal Q2 2020 (quarter ended Sep 30, 2019), unchanged from the prior quarter.

Analysis

Immunovant (IMVT) Non-Current Deffered Revenue (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Immunovant 6.97 Bn 6.97 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 4.03 Mn
Jun 30, 2019 4.03 Mn
API Access

Immunovant Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=IMVT&period=max&api_key=YOUR_API_KEY